Literature DB >> 19002644

Pharmacotherapy of urinary incontinence.

Anastasios Athanasopoulos1, Petros Perimenis.   

Abstract

The pathophysiology of urinary incontinence (UI) involves an overactive detrusor (DOA) or an incompetent urethral sphincter. Therefore, the three most common types of UI are stress urinary incontinence (SUI), urge urinary incontinence (UUI), or a combination of stress and urge known as mixed urinary incontinence (MUI). Pharmacotherapy represents a recognized option for the treatment of different types of UI. A literature search of Medline publications on pharmacological treatment of urinary incontinence until 2008 was performed. Relevant data from recently published literature were included. Anticholinergics are the cornerstone of UUI treatment, whereas serotonin and norepinephrine re-uptake inhibitors represent an option for SUI treatment. A significant percentage of patients with UI, mainly those with UUI and MUI, can be treated successfully with pharmacotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19002644     DOI: 10.1007/s00192-008-0761-1

Source DB:  PubMed          Journal:  Int Urogynecol J Pelvic Floor Dysfunct


  75 in total

Review 1.  Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction.

Authors:  Anastasios Athanasopoulos; Petros Perimenis
Journal:  Expert Opin Pharmacother       Date:  2005-11       Impact factor: 3.889

Review 2.  The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis.

Authors:  Christopher Chapple; Vik Khullar; Zahava Gabriel; Julie Ann Dooley
Journal:  Eur Urol       Date:  2005-03-22       Impact factor: 20.096

3.  Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care.

Authors:  I A O Odeyemi; H A Dakin; R A O'Donnell; J Warner; A Jacobs; P Dasgupta
Journal:  Int J Clin Pract       Date:  2006-08       Impact factor: 2.503

Review 4.  Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review.

Authors:  Paramananthan Mariappan; Ammar Alhasso; Zoe Ballantyne; Adrian Grant; James N'Dow
Journal:  Eur Urol       Date:  2006-09-15       Impact factor: 20.096

5.  Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis.

Authors:  Paul Abrams; Steven Swift
Journal:  Eur Urol       Date:  2005-09       Impact factor: 20.096

6.  Gender difference in the prevalence of clinical depression: the role played by depression associated with somatic symptoms.

Authors:  B Silverstein
Journal:  Am J Psychiatry       Date:  1999-03       Impact factor: 18.112

7.  The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.

Authors:  Karin S Coyne; Chris C Sexton; Debra E Irwin; Zoe S Kopp; Con J Kelleher; Ian Milsom
Journal:  BJU Int       Date:  2008-06       Impact factor: 5.588

8.  Antidiuresis: a new concept in managing female daytime urinary incontinence.

Authors:  D Robinson; L Cardozo; M Akeson; G Hvistendahl; A Riis; J P Norgaard
Journal:  BJU Int       Date:  2004-05       Impact factor: 5.588

9.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226

10.  Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.

Authors:  P Abrams; R Freeman; C Anderström; A Mattiasson
Journal:  Br J Urol       Date:  1998-06
View more
  1 in total

1.  Analysis of clinical interventional strategy for women with urinary incontinence complicated with diabetes mellitus.

Authors:  Yu-xin Zhang; Hai-nan Xu; Zhi-jun Xia; Bo Wu
Journal:  Int Urogynecol J       Date:  2011-09-29       Impact factor: 2.894

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.